NeOProM

NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol

http://www.biomedcentral.com/1471-2431/11/6
I am just presenting the summary of evidence as of now. Very interesting though!
In the Benefits of Oxygen Saturation Targeting (BOOST) trial , 358 infants born at less than 30 weeks' gestation were randomly assigned, from 3 weeks or more after birth until they breathed air, to target a SpO₂ range of either 91-94% or 95-98%. This trial found no evidence that higher SpO₂ targeting improved growth or development, but it did increase days of oxygen therapy and use of health care resources.
In a more recent cohort study, Tin et al that lower SpO₂ correlated with improved short term respiratory and growth outcomes in infants born at less than 28 weeks' gestation.
Babies in the neonatal intensive care units (NICU) targeting SpO₂ 70-90% had ROP surgery less often than those in the NICUs targeting SpO₂ 88-98% (6.2% v 27.2%, 80% relative risk reduction (RRR), p < style="color: rgb(153, 102, 51); font-style: italic;">ventilated less often (13.9 v 31.4 days), fewer needed oxygen at 36 weeks' postmenstrual age (18% v 46%, 61% RRR), and fewer were below the 3rd centile for weight at discharge (17% v 45%, 62% RRR) (all p <>v 53%) and cerebral palsy (15% v 17%) at one year were similar.